Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica

被引:87
作者
Lopez-Hoyos, M
de Alegria, CR
Blanco, R
Crespo, J
Peña, M
Rodriguez-Valverde, V
Martinez-Taboada, VM [1 ]
机构
[1] Univ Cantabria, Fac Med, Hosp Univ Marques de Valdecilla, Rheumatol Serv, Santander 39008, Spain
[2] Univ Cantabria, Fac Med, Hosp Univ Marques de Valdecilla, Serv Immunol, Santander 39008, Spain
关键词
polymyalgia rheumatica; rheumatoid arthritis; elderly; anti-CCP antibodies;
D O I
10.1093/rheumatology/keh143
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. In a significant number of patients the differential diagnosis between elderly-onset rheumatoid arthritis (EORA) and polymyalgia rheumatica (PMR) is very difficult because of the lack of specific serum markers. Anti-cyclic citrullinated peptide antibodies (anti-CCP Abs) have recently been shown to be highly specific for rheumatoid arthritis (RA). This is the first study addressing the utility of these antibodies in the differential diagnosis between EORA and PMR. Methods. Serum samples from 57 EORA patients and 49 PMR patients were studied for the presence of anti-CCP Abs and rheumatoid factor (RF). As controls, samples from 41 RA patients (age at onset <60 yr) and 24 aged healthy subjects were analysed. Results. Sixty-five per cent of EORA patients had anti-CCP Abs, whereas none of the PMR patients or the aged healthy subjects was positive for those antibodies. Ten of the EORA patients started with polymyalgic symptoms and two of them were positive for anti-CCP Abs. Interestingly, there was a significant correlation between anti-CCP Abs and RF in EORA but not in young RA patients. Conclusions. The presence of anti-CCP Abs in a patient with clinical symptoms of PMR must be interpreted as highly suggestive of EORA.
引用
收藏
页码:655 / 657
页数:3
相关论文
共 15 条
[1]  
ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315
[2]  
Bajocchi G, 2000, CLIN EXP RHEUMATOL, V18, pS49
[3]   EVALUATION OF CRITERIA FOR POLYMYALGIA RHEUMATICA [J].
BIRD, HA ;
ESSELINCKX, W ;
DIXON, ASJ ;
MOWAT, AG ;
WOOD, PHN .
ANNALS OF THE RHEUMATIC DISEASES, 1979, 38 (05) :434-439
[4]   Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study [J].
Caporali, R ;
Montecucco, C ;
Epis, O ;
Bobbio-Pallavicini, F ;
Maio, T ;
Cimmino, MA .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (11) :1021-1024
[5]   POLYMYALGIA RHEUMATICA - A 10-YEAR EPIDEMIOLOGIC AND CLINICAL-STUDY [J].
CHUANG, TY ;
HUNDER, GG ;
ILSTRUP, DM ;
KURLAND, LT .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (05) :672-680
[6]  
Fito C, 1998, ARTHRITIS RHEUM, V41, pS356
[7]   Filaggrin related antibodies among the aged [J].
Palosuo, T ;
Tilvis, R ;
Strandberg, T ;
Aho, K .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (03) :261-263
[8]   Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica [J].
RodriguezValverde, V ;
Sarabia, JM ;
GonzalezGay, MA ;
Figueroa, M ;
Armona, J ;
Blanco, R ;
FernandezSueiro, JL ;
MartinezTaboada, VM .
AMERICAN JOURNAL OF MEDICINE, 1997, 102 (04) :331-336
[9]   Medical progress - Polymyalgia rheumatica and giant-cell arteritis [J].
Salvarani, C ;
Cantini, F ;
Boiardi, L ;
Hunder, GG .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (04) :261-271
[10]   Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies [J].
Schellekens, GA ;
de Jong, BAW ;
van den Hoogen, FHJ ;
van de Putte, LBA ;
van Venrooij, WJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (01) :273-281